Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 41–50, page 5 of 20. Filter these by subject, year and score in the research library →

1. Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotesResearch summary

   Research summaries · alzhub.org/study/lecanemab-for-treatment-of-individuals-with-early-alzheimer-s-disease-41689888

   … non-carriers (85 %). Lecanemab significantly reduced clinical decline on CDR-SB at 18 months compared to placebo in the ApoEε4 heterozygotes or non-carriers subgroup. Amyloid PET, ADAS-Cog14, ADCS-MCI-ADL, and HRQoL results were …

2. Lecanemab reduces brain amyloid-β and delays cognitive worseningResearch summary

   Research summaries · alzhub.org/study/lecanemab-reduces-brain-amyloid-and-delays-cognitive-worsening-36948153

   Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized …

3. Long-term value of lecanemab to individuals and familiesResearch summary

   Research summaries · alzhub.org/study/long-term-value-of-lecanemab-to-individuals-and-families-40895811

   An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health-care providers important information for deciding treatment initiation. We used data …

4. The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microgliaResearch summary

   Research summaries · alzhub.org/study/the-alzheimer-s-therapeutic-lecanemab-attenuates-a-pathology-by-41286448

   … we demonstrate that Lecanemab, a leading anti-β-amyloid (Aβ) antibody, mediates amyloid clearance by activating microglial effector functions. Using a human microglia xenograft mouse model, we show that Lecanemab significantly …

5. Krankheitsmodifizierende Therapie mit Lecanemab bei früher Alzheimer-DemenzResearch summary

   Research summaries · alzhub.org/study/krankheitsmodifizierende-therapie-mit-lecanemab-bei-fruher-alzheimer-41052542

   … AD zu verlangsamen. Lecanemab ist durch den Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) für die Zulassung bei Patienten mit früher AD unter zwei Bedingungen empfohlen worden. Erstens sollen …

6. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-clarity-ad-quality-of-life-results-from-a-randomized-double-37874099

   A total of 1795 participants were enrolled (lecanemab:898; placebo:897). At month 18, adjusted mean change from baseline in EQ-5D-5L and QOL-AD by subject showed 49% and 56% less decline, respectively. QOL-AD rated by study …

7. Lecanemab en la enfermedad de AlzheimerResearch summary

   Research summaries · alzhub.org/study/lecanemab-en-la-enfermedad-de-alzheimer-ab04d0ab

   … anticuerpos monoclonales, como lecanemab y donanemab, han mostrado su capacidad de eliminar, de forma rápida y sustancial, las placas cerebrales y han producido recientemente resultados cognitivos y clínicos alentadores en …

8. FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/fda-approves-leqembi-lecanemab-irmb-under-the-accelerated-approval-149a0541

   The FDA gave lecanemab (Leqembi) accelerated approval based on Phase 2 data showing it reduced amyloid plaque in the brain, ahead of full Phase 3 results. The label carried a warning about ARIA (amyloid-related imaging …

9. Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinicsResearch summary

   Research summaries · alzhub.org/study/lecanemab-for-early-alzheimer-s-disease-appropriate-use-40011173

   Lecanemab, a monoclonal antibody targeting β-amyloid protofibrils, has shown promising results in a Phase III clinical trial for the treatment of early stages of Alzheimer's disease (AD) and has been approved by the European …

10. Real-world implementation of lecanemab in Alzheimer's disease: A Japanese cohortResearch summary

    Research summaries · alzhub.org/study/real-world-implementation-of-lecanemab-in-alzheimer-s-disease-a-42798750

    Introduction Real-world evidence for lecanemab remains limited, particularly among Asian populations. We evaluated the feasibility, safety, biomarker profiles, and short-term clinical outcomes of lecanemab in practice in Japan. …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.